Vivek Ramaswamy engineers new deal with RTW to take Pete Salzmann's Immunovant public
Several weeks after pulling out of an IPO for Dermavant, Vivek Ramaswamy has found a different route for another of his biotechs to go public.
Immunovant is merging with Health Sciences Acquisitions Corporation, a $115 million blank check company sponsored by RTW Investments and backed by Adage Capital, Cormorant, Eventide and Perceptive Advisors. In addition to around $100 million confirmed to be in the bank, RTW and Roivant, alongside BVF Partners, have put together a $35 million private “bridge financing.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.